⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556824 | 0.77 | ALDH1A1 (0.30) | — | |
| SCHEMBL5598585 | 0.65 | — | — | |
| SCHEMBL3675121 | 0.63 | PTPN1 (0.31) | — | |
| SCHEMBL17865612 | 0.59 | — | — | |
| SCHEMBL10375234 | 0.59 | PTPN1 (0.38) | — | |
| SCHEMBL1482396 | 0.57 | ALDH1A1 (0.32) | — | |
| SCHEMBL11945783 | 0.57 | ALDH1A1 (0.36) | — | |
| SCHEMBL28541827 | 0.57 | — | — | |
| SCHEMBL4644591 | 0.57 | — | — | |
| SCHEMBL24387455 | 0.54 | AKR1B1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577231-B2 | Androgen receptor PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| WO-2025061906-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-27 | — | — | WO | disclosed |
| US-20230091225-A1 | Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2023-03-23 | — | — | US | disclosed |
| EP-3957633-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2022-02-23 | — | — | EP | disclosed |
| CN-111825657-A | Dual-function chimeric heterocyclic compound for targeted degradation of androgen receptor and application thereof | 成都海创药业有限公司 | 2020-10-27 | — | — | CN | disclosed |
| WO-2020211822-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | 成都海创药业有限公司 | 2020-10-22 | — | — | WO | disclosed |
| WO-2020211822-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | 成都海创药业有限公司 | 2020-10-22 | — | — | WO | disclosed |